Kidney function may change how this drug works

NCT ID NCT07694869

Recruiting now Knowledge-focused Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This Phase 1 trial studies how the drug ammoxetine hydrochloride is processed in people with moderate kidney impairment compared to those with normal kidney function. Sixteen adults receive the drug daily for six days, and researchers measure drug levels in blood and urine. The goal is to understand if kidney problems affect drug exposure and safety, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ammoxetine hydrochloride
What this could lead to: If successful, this study could help determine safe dosing of ammoxetine for people with moderate kidney problems.
What could go wrong: This is a very early Phase 1 trial with only 16 participants, so results may not apply broadly. The drug may cause side effects or behave differently than expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS PARTICIPANTS WITH MODERATE RENAL IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, Anhui, 230022, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.